Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 4.55 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $334.978 million which beat the analyst consensus estimate of $314.226 million by 6.60 percent. This is a 44.33 percent increase over sales of $232.088 million the same period last year.